Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban
Research and Practice in Thrombosis and Haemostasis · 2026-10 · 10 (7) · 106968
DOI: 10.1016/j.rpth.2026.106968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026-10. Verfasst von Parwana Hussaini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Venous Thromboembolism, Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Clinical characteristics and outcomes of patients with cancer with symptomatic vs incidental venous thromboembolism (VTE) remain poorly described.
Methods
In this post hoc analysis of the apixaban as treatment of venous thrombosis in patients with cancer (CAP) study, we explored patients with cancer with VTE who received apixaban 5 mg twice daily for 6 months and then 2.5 mg twice daily for 30 months. Patients were classified as having symptomatic or incidental VTE at inclusion. The main outcomes were recurrent VTE and clinically relevant bleeding. Baseline characteristics and outcomes were compared between the 2 groups during a 36-month follow-up.
Results
Of 284 patients, 163 (57%) had incidentally detected VTE. Compared with symptomatic patients, incidental patients had lower body mass index, more metastatic disease (79% vs 57%), and more pulmonary embolism or abdominal vein thrombosis. Deep vein thrombosis of the leg was more frequent in the symptomatic group (45.4% vs 7.4%, P < .001). There were more colorectal cancers in the incidental group (31.9% vs 19.0%, P = .01) and more hematological (14.1% vs 5.5%, P = .01) or breast cancers (14.9% vs 5.5%, P = .01) in the symptomatic group. Recurrent VTE occurred in 9.8% of incidental and 6.6% of symptomatic patients (subdistribution hazard ratio, 1.5; 95% CI, 0.6-3.5). Clinically relevant bleeding was more frequent in the incidental group (24.5% vs 13.2%; subdistribution hazard ratio, 1.9; 95% CI, 1.1-3.4). In the multivariable analysis, low hemoglobin and incidental VTE were independently associated with bleeding.
Conclusion
The characteristics and outcomes in patients with incidental VTE differed from those with symptomatic VTE. While VTE recurrence was similar between the two groups, incidental VTE was associated with a higher risk of bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Hematology, Akershus University Hospital, Lørenskog, Norway.
- Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway.
Zitieren
APA
Hussaini, P., Larsen, T. L., Ghanima, W., & Astrup Dahm, A. E. (2026). Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban. Research and Practice in Thrombosis and Haemostasis, 10(7), 106968. https://doi.org/10.1016/j.rpth.2026.106968
Vancouver
Hussaini P, Larsen TL, Ghanima W, Astrup Dahm AE. Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban. Research and Practice in Thrombosis and Haemostasis. 2026;10(7):106968. doi:10.1016/j.rpth.2026.106968
BibTeX
@article{Hussaini2026,
author = {Hussaini, Parwana and Larsen, Trine-Lise and Ghanima, Waleed and Astrup Dahm, Anders Erik},
title = {Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
volume = {10},
number = {7},
pages = {106968},
doi = {10.1016/j.rpth.2026.106968}
}
EUVIMED